Purification and Characterization of an Immunogenic Aminopeptidase of<i>Brucella melitensis</i>

Contreras-Rodríguez, Araceli; Ramı́rez-Zavala, Bernardo; Contreras, Andrea; Schurig, Gerhardt G.; Sriranganathan, Nammalwar; López-Merino, Ahidé

doi:10.1128/iai.71.9.5238-5244.2003

Cited by 24 publications

(24 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…melitensis 16M (virulent strain) and B. melitensis Rev.1 (vaccine strain) were grown under optimal conditions as described elsewhere [34]. E. coli TOP10 and BL21 (DE3) (a gift from Dr. Pourmand, Tehran University of Medical Sciences) were used for expression of the recombinant proteins.…”

Section: Bacterial Strainsmentioning

confidence: 99%

Simultaneous immunization of mice with Omp31 and TF provides protection against Brucella melitensis infection

Ghasemi

Jeddi-Tehrani

Mautner

et al. 2015

Vaccine

View full text Add to dashboard Cite

Section: Bacterial Strainsmentioning

confidence: 99%

Simultaneous immunization of mice with Omp31 and TF provides protection against Brucella melitensis infection

Ghasemi

Jeddi-Tehrani

Mautner

et al. 2015

Vaccine

View full text Add to dashboard Cite

“…B. melitensis is predominantly a disease of goats ( Capra hircus ) and sheep ( Ovis aries ), but can infect cattle as well (Zowghi and Ebadi, 1985; Buyukcangaz and Sen, 2007), causing placentitis. It is considered the most pathogenic species to humans (Corbel, 1997; Contreras-Rodriguez et al, 2003; Eschenbrenner et al, 2006), at least by the median infective dose by aerosol exposure (Teske et al, 2011), although B. abortus appears to cause equally severe disease (Atluri et al, 2011). B. suis infects a broad range of animals, including swine ( Sus spp.…”

Section: Introductionmentioning

confidence: 99%

Progress in Brucella vaccine development

et al. 2012

View full text Add to dashboard Cite

Brucella spp. are zoonotic, facultative intracellular pathogens, which cause animal and human disease. Animal disease results in abortion of fetuses; in humans, it manifests flu-like symptoms with an undulant fever, with osteoarthritis as a common complication of infection. Antibiotic regimens for human brucellosis patients may last several months and are not always completely effective. While there are no vaccines for humans, several licensed live Brucella vaccines are available for use in livestock. The performance of these animal vaccines is dependent upon the host species, dose, and route of immunization. Newly engineered live vaccines, lacking well-defined virulence factors, retain low residual virulence, are highly protective, and may someday replace currently used animal vaccines. These also have possible human applications. Moreover, due to their enhanced safety and efficacy in animal models, subunit vaccines for brucellosis show great promise for their application in livestock and humans. This review summarizes the progress of brucellosis vaccine development and presents an overview of candidate vaccines.

show abstract

“…Peptide metabolism by APN was optimal at pH 7.0 and was inhibited by bestatin (Ki = 2.2 µM) and amastatin (Ki = 0.025 µM). [47].…”

Section: Natural Substrates For Apnmentioning

confidence: 95%

Progress in the Development of Aminopeptidase N (APN/CD13) Inhibitors

Xu¹,

2005

CMCACA

View full text Add to dashboard Cite

Aminopeptidase N (APN; CD13) is a member of zinc-containing ectoenzymes family involved in the degradation of neutral or basic amino acids (Ala>Phe>Leu>Gly) from N-terminal of bioactive peptides and amide or arylamide derivatives of amino acids. The expression of APN being up regulated has been implicated in the pathogenesis of a variety of diseases such as cancer, leukemia, diabetic nephropathy, and rheumatoid arthritis. Thus, APN inhibitors (APNIs) are expected to be useful for the treatment of these disorders. This article reviews briefly the structure characteristic and possible function of APN. The proposed biomolecular structures and mechanism of action used in the design of APNIs are thoroughly covered. Major emphasis is on recently published potent, small molecular weight APNIs and their essential structure activity relationship (SAR). Finally, available clinical results of compounds in development are summarized in this review.

show abstract

Purification and Characterization of an Immunogenic Aminopeptidase ofBrucella melitensis

Cited by 24 publications

References 33 publications

Simultaneous immunization of mice with Omp31 and TF provides protection against Brucella melitensis infection

Simultaneous immunization of mice with Omp31 and TF provides protection against Brucella melitensis infection

Progress in Brucella vaccine development

Progress in the Development of Aminopeptidase N (APN/CD13) Inhibitors

Contact Info

Product

Resources

About